Deulumateperone

Deulumateperone
Clinical data
Other namesLumateperone deuterated; Deuterated lumateperone; ITI-1284; ITI1284; ITI-1284-ODT-SL
Routes of
administration		Sublingual (orally disintegrating tablet)[1]
Drug classAtypical antipsychotic
Identifiers
IUPAC name
  • 1-(4-fluorophenyl)-4-[(6bR,10aS)-3-methyl-2,3,6b,9,10,10a-(2-2H)hexahydro(2-2H)-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]butan-1-one
CAS Number
Chemical and physical data
FormulaC24H26D2FN3O
Molar mass395.518 g·mol−1
3D model (JSmol)
SMILES
  • CN1C([2H])([2H])CN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F
InChI
  • InChI=1S/C24H28FN3O/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3/t20-,21-/m0/s1/i14D2
  • Key:HOIIHACBCFLJET-FTHFLAHXSA-N

Deulumateperone (INNTooltip International Nonproprietary Name; developmental code name ITI-1284) is an experimental antipsychotic of the pyridopyrroloquinoxaline and butyrophenone families as well as a deuterated analogue of lumateperone which is under development as a sublingually administered orally disintegrating tablet (ODT) for the treatment of psychotic disorders, agitation, and generalized anxiety disorder.[2][3][4][1] No recent development has been reported for treatment of depressive disorders, behavioral disorders, and dementia.[2] It is being developed by Intra-Cellular Therapies.[2][3][1] As of January 2025, it has reached phase 2 clinical trials.[2][3]

  1. ^ a b c Oguma T, Jino K (2024). "Clinical Pipelines for Alzheimer's Disease Psychosis and Agitation". Chemical & Pharmaceutical Bulletin. 72 (7): 610–617. doi:10.1248/cpb.c23-00416. PMID 38945937.
  2. ^ a b c d "Intra-Cellular Therapies". AdisInsight. 29 January 2025. Retrieved 26 February 2025.
  3. ^ a b c "Delving into the Latest Updates on ITI-1284 with Synapse". Synapse. 20 February 2025. Retrieved 26 February 2025.
  4. ^ "Proposed INN: List 132 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 38 (4): 1073. 2024.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.